Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02155452
Other study ID # TMC- ACTREC IRB project no 139
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 2014
Est. completion date July 2019

Study information

Verified date May 2022
Source Tata Memorial Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators aim to study the heterogeneity of fluorescence within malignant gliomas by sampling tissues from these variable areas within the same tumor. These tissue samples will then be subjected to pathological and biological analysis to assess proteins related to ALA metabolism and correlated with the fluorescence emitted as well as levels of protoporphyrin IX in the tissues.


Description:

Malignant gliomas are the commonest malignant brain tumors but are extremely challenging to treat. Neuro-oncology has seen little progress in its treatment despite extensive research. Extent of resection remains a very important prognostic factor in these tumors. Better the resection, better the outcomes. However resecting these tumors is not very easy primarily due to their infiltrative nature and difficulty in discerning tumor boundaries intraoperatively. Fluorescence guided resection (FGR) has recently been shown to be a very important and useful adjunct in maximizing this goal. FGR involves administration of aminolevulinic acid (ALA) to the patient prior to surgery. The ALA is converted to protoporphyrin IX (PPIX) in glioma cells. The PPIX is a fluorophore and can be visualized intraoperatively using a suitably modified microscope. Neurosurgeons can then resect the tumor radically guided by this fluorescence which is superior to the conventional microscopic resection. Selective PPIX accumulation in glioma cells is the key to the accuracy of this technique. The biological basis of selectivity of PPIX accumulation within glioma cells is however poorly understood. Various mechanisms could be involved starting from variable transport (related to blood-brain barrier properties), differential uptake (governed by active transport mechanisms) and differential metabolism within the cell. Understanding these mechanisms can lead to refinements in this strategy, overcoming its present limitations and development of methods to extend its scope.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date July 2019
Est. primary completion date July 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: Per-primum glioma - Adults (18-65 years) - Radiologically suspected malignant gliomas - Variable contrast enhancement on MRI (patchy and/or non-uniform) - Eligible for surgical therapy (craniotomy NOT stereotactic biopsy ) - No contraindication for surgery Exclusion Criteria: - Poor general condition (KPS < 70) - Prior treatment (except biopsy) - Compromised renal/hepatic function - Immunocompromised status - Known photosensitivity / allergy to 5-ALA

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
ALA
Prior to surgery all patients would receive freshly prepared solution of 5-ALA, 20 mg/kg bodyweight dissolved in 100 ml of potable water orally approximately 4 hours (range 4-6 hrs) before the commencement of anesthesia induction for surgery. The surgery would then be performed with the help of navigation. After craniotomy, the navigation software would be used to identify the selected target areas based on the preoperative images (MR as well as PET when available) and directed image-guided biopsies from these representative areas will be collected for histological evaluation

Locations

Country Name City State
India Advanced Centre for Treatment, Research & Education in Cancer (ACTREC) Navi Mumbai Maharashtra

Sponsors (1)

Lead Sponsor Collaborator
Tata Memorial Hospital

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Degree of fluorescence Degree of fluorescence in different tumor regions
PPIX Qualification
At the time of surgery within 72 hours
Secondary High throughput proteomic screening of tissue samples -A quantitative approach will be undertaken to compare the proteome profile Postoperatively within 1 week of the excision
See also
  Status Clinical Trial Phase
Recruiting NCT03212742 - Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients Phase 1/Phase 2
Recruiting NCT01657734 - Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy N/A
Completed NCT00165477 - Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme Phase 2
Completed NCT00879437 - Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma Phase 2
Completed NCT02632370 - 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
Completed NCT00590954 - Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas Phase 2
Completed NCT00822887 - Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas Phase 1
Terminated NCT00923117 - Sunitinib to Treat Recurrent Brain Cancer Phase 2
Completed NCT02731521 - Clinical Development of MR Spectroscopy and Imaging in Brain Cancers
Completed NCT02388659 - Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas
Terminated NCT01549392 - Imaging Study of Glioblastomas Treated With Avastin N/A
Completed NCT00272350 - ZD6474 to Treat Advanced Brain Cancer in Patients Phase 1
Completed NCT00271609 - Bevacizumab for Recurrent Malignant Glioma Phase 2
Completed NCT00074646 - Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas Phase 1
Recruiting NCT01670890 - Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas Phase 2
Completed NCT00704080 - A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas Phase 1
Completed NCT00463073 - Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas Phase 2
Terminated NCT00671801 - Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I Phase 1
Withdrawn NCT02369367 - Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme (Phase II) Phase 2